Glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for diabetes management, have emerged as a promising treatment for obesity
Results may depend on lifestyle factors like diet and physical activity
GI symptoms from retatrutide introduction are expected and should be managed with dietary adjustments, smaller meals, and adequate hydration
Chang and colleagues showed in 2011 that the peptide upregulates growth-hormone receptor expression on tendon fibroblasts and increases their migration and survival in culture, an effect that has been reproduced across several Achilles- and quadriceps-tendon transection models in rats
So far, the main therapeutic strategies for weight reduction and obesity control are lifestyle interventions, anti-obesity medications, and endoscopic and bariatric surgeries or combination therapies ( The intestinal microbiota is now considered to be a new complex organ, consisting of 5001,000 bacterial species with the amount up to 10 14 , and the number of genes in the intestinal microbiota is approximately 100 times of that in humans ( Firmicutes and Bacteroidetes , and their ratios, have been linked to the development of obesity in population ( Firmicutes -to- Bacteroidetes ratio, a decline in beneficial metabolite-producing bacteria such as short-chain fatty acids (SCFAs) (Turnbaugh et al., 2006)
